Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of a hedgehog signaling pathway inhibitor in the preparation of a medicament for treating egfr overexpressed cancer

A medicament and a technology of use, applied in the field of use of Hedgehog signaling pathway inhibitors in the preparation of medicaments for the treatment of EGFR-overexpressed cancers

Active Publication Date: 2021-07-02
JIANGSU HENGRUI MEDICINE CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no literature mentioning the association of such Hedgehog signaling pathway inhibitors with EGFR-TKI resistant cancers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a hedgehog signaling pathway inhibitor in the preparation of a medicament for treating egfr overexpressed cancer
  • Use of a hedgehog signaling pathway inhibitor in the preparation of a medicament for treating egfr overexpressed cancer
  • Use of a hedgehog signaling pathway inhibitor in the preparation of a medicament for treating egfr overexpressed cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Evaluate the synergistic effect of Hedgehog inhibitor compound (I) on erlotinib on the human lung cancer NCI-H292 model with high expression of EGFR that induces resistance to erlotinib in vivo

[0016] 1 test drug

[0017] The test compound (I) was synthesized with reference to the content disclosed in CN103261198A. Preparation method: compound (I) is prepared with 0.2% Tween 80+0.5% CMC; erlotinib (erlotinib hydrochloride) is prepared with 0.2% Tween80 distilled water.

[0018] 2 experimental animals

[0019] BALB / cA-nude nude mice, 6-7 weeks old, ♀, were purchased from Shanghai Slack Experimental Animal Co., Ltd. Certificate number: SCXK (Shanghai) 2007-0005. Breeding environment: SPF grade.

[0020] 3 experimental steps

[0021] Nude mice were subcutaneously inoculated with human lung cancer NCI-H292 cells until the tumor grew to 100-250mm 3 Afterwards, the animals were randomly divided into groups (D0). See Table 1 for dosage and regimen. The tum...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Use of a Hedgehog signaling pathway inhibitor in the preparation of medicines for treating EGFR overexpressed cancer. The Hedgehog signaling pathway inhibitor can also be used in combination with an EGFR inhibitor. The present invention also relates to a pharmaceutical composition comprising the above two inhibitors.

Description

technical field [0001] The invention relates to the use of a Hedgehog inhibitor in the preparation of a medicine for treating EGFR overexpressed cancer. Background technique [0002] Lung cancer is one of the malignant tumors with the fastest increasing morbidity and mortality and the greatest threat to the health and life of the population. In 2015, China is expected to have 4.292 million new cancer cases and 2.814 million deaths. Lung cancer is the tumor with the highest incidence rate and the leading cause of cancer death. The morbidity and mortality of male lung cancer accounted for the first of all malignant tumors, and the incidence and mortality of females accounted for the second. [0003] Epidermal growth factor receptor tyrosinase inhibitors (EGFR-TKI) are currently the most widely used and most successful class of drugs in the treatment of non-small cell lung cancer (NSCLC) molecular targeted therapy. Sales of EGFR-TKI drugs, such as gefitinib, erlotinib, afati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/5025A61P35/00A61K31/517A61K31/5377A61K31/519
CPCA61K31/5025A61K31/517A61K31/519A61K31/5377A61K2300/00
Inventor 孙飘扬曹国庆唐蜜杨昌永张连山
Owner JIANGSU HENGRUI MEDICINE CO LTD